Key insights
-
1
Management separated “normalized” EBITDA from timing-related items: Management anchored “normalized” 2025 adjusted EBITDA at $300 million and said about $20 million of the updated 2025 adjusted EBITDA guidance reflects timing-related items not expected to recur in 2026.
-
2
2026 guidance excluded future M&A impacts: Management said initial 2026 guidance does not include any impact from future mergers or acquisitions.
-
3
Growth expectations emphasized volume over rate: Executives indicated they expect growth to be driven more by volume than rate across most of the business.
Takeaways
Aveanna projected higher 2025 results and steady adjusted EBITDA into 2026 while emphasizing preferred-payer expansion, Medicaid rate efforts, liquidity, deleveraging, and free-cash-flow generation.
Topics
Business & Markets Management Health & Medicine Healthcare Systems